Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 152,925 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Condition Clear all
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

NCT05511363
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
KarXT, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
55 Years to 90 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
59
States / cities
Homewood, Alabama • Phoenix, Arizona • Encino, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 28, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

NCT04480463
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions
SCD411, Aflibercept
Drug
Lead sponsor
Sam Chun Dang Pharm. Co. Ltd.
Industry
Eligibility
50 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Campbell, California • Clearwater, Florida • Coral Springs, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 28, 2026, 9:16 AM EDT
Not listed Not applicable Interventional

Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes

NCT03953963
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Resistance
Interventions
HydraSolve T2D™
Device
Lead sponsor
Medality Medical
Industry
Eligibility
22 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 28, 2026, 9:16 AM EDT
Active, not recruiting Not applicable Interventional

Multichannel Vestibular Implant Early Feasibility Study

NCT02725463
View directory record Official record
Conditions
Other Disorders of Vestibular Function, Bilateral, Bilateral Vestibular Deficiency (BVD), Gentamicin Ototoxicity, Labyrinth Diseases, Vestibular Diseases, Sensation Disorders
Interventions
Labyrinth Devices MVI™ Multichannel Vestibular Implant
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 28, 2026, 9:16 AM EDT
Completed No phase listed Observational

Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure

NCT03387163
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
Sacubitril/Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 28, 2026, 9:16 AM EDT
Completed No phase listed Observational

Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)

NCT01873963
View directory record Official record
Conditions
Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
Not listed
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
11
States / cities
Aurora, Colorado • Miami, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 28, 2026, 9:16 AM EDT
Terminated Phase 1 Interventional

A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer

NCT03300921
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Paricalcitol
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 28, 2026, 9:16 AM EDT
Suspended Phase 4 Interventional

Preimplantation Genetic Diagnosis for the Indication of Advanced Reproductive Age

NCT00646893
View directory record Official record
Conditions
Infertility
Interventions
Preimplantation Genetic Diagnosis (PGD)
Procedure
Lead sponsor
Reprogenetics
Industry
Eligibility
37 Years to 42 Years · Female only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Beverly Hills, California • Highland Park, Illinois • Livingston, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 23, 2010 · Synced Oct 28, 2026, 9:16 AM EDT
Completed Phase 4 Interventional Results available

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

NCT01475721
View directory record Official record
Conditions
Asthma
Interventions
ADVAIR 100/50mcg, ADVAIR 250/50mcg, ADVAIR 500/50mcg, FLOVENT 100mcg, FLOVENT 250mcg, FLOVENT 500mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
11,751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
350
States / cities
Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 273 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 28, 2026, 9:16 AM EDT
Enrolling by invitation No phase listed Observational

Youth Depression and Suicide Research Network

NCT04572321
View directory record Official record
Conditions
Depression, Suicide, Suicidal Ideation, Suicide, Attempted, Depressive Disorder, Depressive Symptoms, Depressive Episode, Depression and Suicide, Depression, Teen, Depression, Anxiety
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years to 20 Years
Enrollment
5,000 participants
Timeline
2020 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 28, 2026, 9:16 AM EDT
Terminated Phase 2 Interventional Results available

Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure

NCT00113321
View directory record Official record
Conditions
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Interventions
Decitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 28, 2026, 9:16 AM EDT
Recruiting Not applicable Interventional

A Study to Evaluate the Cariostatic Efficacy of Nano Silver Fluoride (NSF) vs. Silver Diamine Fluoride (SDF) in Children

NCT07861321
View directory record Official record
Conditions
Dental Caries
Interventions
Nano Silver Fluoride / NSF
Device
Lead sponsor
A.T. Still University of Health Sciences
Other
Eligibility
6 Years to 10 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

NCT02284893
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Dapagliflozin, Sitagliptin, Placebo matching with Saxagliptin, Placebo matching with Dapagliflozin, Placebo matching with Sitagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 28, 2026, 9:16 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy Evaluation of the Mosaic Ultra Device

NCT06117293
View directory record Official record
Conditions
Skin Texture Disorder, Photoaging, Wrinkle, Scar, Stretch Mark, Acne Vulgaris, Hair Loss
Interventions
Mosaic
Device
Lead sponsor
CynosureLutronic
Industry
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Lincolnshire, Illinois • Billerica, Massachusetts • Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 28, 2026, 9:16 AM EDT
Not listed Phase 4 Interventional

PREvent First Episode Relapse (PREFER)

NCT00220714
View directory record Official record
Conditions
Schizophrenia
Interventions
atypical antipsychotics:oral vs. long-acting route, Family Psychoeducation
Drug · Behavioral
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
16 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2008 · Synced Oct 28, 2026, 9:16 AM EDT
Terminated Phase 1 Interventional Results available

Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab

NCT03286114
View directory record Official record
Conditions
Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Interventions
Pembrolizumab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 28, 2026, 9:16 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Electrical Inhibition (EI): A Preliminary Study To Inhibit Preterm Labor And Preterm Birth

NCT02569216
View directory record Official record
Conditions
Premature Birth, Premature Labor
Interventions
Electrical Inhibition (EI)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 28, 2026, 9:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Trial of Liposomal Bupivacaine for TKA

NCT05635916
View directory record Official record
Conditions
Knee Replacement, Total Knee Arthroplasty, Post-Operative Pain
Interventions
Liposomal bupivacaine, Bupivacaine
Drug
Lead sponsor
Northern Light Mercy Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 28, 2026, 9:16 AM EDT
Completed Not applicable Interventional

Comparing Different Types of Physical Therapy for Treating People With a Meniscal Tear and Osteoarthritis

NCT03059004
View directory record Official record
Conditions
Meniscal Degeneration, Osteoarthritis, Knee
Interventions
TeMPO Home Exercise Program, Motivational SMS Messages, In-Clinic Topical Therapy, In-Clinic Exercise Therapy
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 85 Years
Enrollment
879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
Boston, Massachusetts • Buffalo, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 28, 2026, 9:16 AM EDT
Active, not recruiting Phase 1 Interventional

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

NCT04337177
View directory record Official record
Conditions
Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
Interventions
VAL-413, Temozolomide
Drug
Lead sponsor
Valent Technologies, LLC
Industry
Eligibility
1 Year to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 28, 2026, 9:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Study to Assess the Effects of JoyRise Recovery Powder on Mitigating Alcohol Aftereffects.

NCT06575972
View directory record Official record
Conditions
Alcohol Aftereffects, Anxiety, Cognitive Impairment
Interventions
JoyRise Recovery Powder, Placebo
Dietary Supplement
Lead sponsor
Joyrise
Industry
Eligibility
35 Years to 54 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 28, 2026, 9:16 AM EDT
Completed Not applicable Interventional

Fit for Two: Incorporating Wearable Trackers Into Clinical Care for Pregnant Women With Diabetes (FFT)

NCT03302377
View directory record Official record
Conditions
Physical Activity, Type 2 Diabetes Mellitus
Interventions
physical activity counseling & Fitbit
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 28, 2026, 9:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Family-Authored ICU Diaries to Reduce Fear in Patients Experiencing a Cardiac Arrest (FAID Fear)

NCT05144477
View directory record Official record
Conditions
Cardiac Arrest, Post Traumatic Stress Syndrome
Interventions
FAID Fear Intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 28, 2026, 9:16 AM EDT
Completed Phase 1 Interventional

Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme

NCT00509301
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
131-I-chTNT-1/B MAB
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
Phoenix, Arizona • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 28, 2026, 9:16 AM EDT